A global leader in digital health technologies

Adherium is a global leader in digital health technologies which address sub-optimal medication use in chronic disease.

Its Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease.

Adherium has the broadest range of "smart" devices for respiratory medications globally. Adherium Smartinhalers attach to prescription inhalers to provide reminders and monitoring of inhaler usage.

The SmartinhalerLive platform uses wireless communications technology to provide real time data collection and reporting from the Company’s Smartinhalers.

Smartinhaler™ technology has been independently shown to:
  • Increase adherence to preventative medication by 180% in children and 59% in adults;
  • Reduce severe exacerbations in adults by 60%; and
  • Contribute to significant improvements in quality of life for people with chronic asthma.

The Smartinhaler™ platform has been used in over 60 projects (clinical, device validation or other) and has peer reviewed journal articles resulting from 14 studies. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

The Executive Team

Adherium has a committed, multi-disciplinary management team, focused on achieving our objective of being the international leader in digital health technologies which address sub-optimal medication use in chronic disease.

Arik Anderson, Bsc.
Arik Anderson, Bsc.

Group CEO

Mr Anderson has 25 years of experience in the medical technology and medical device manufacturing industries and has led significant growth for emerging technology companies. He was previously President, Perfusion and Surgical Devices Division for Terumo Cardiovascular since 2011. Prior to this Mr Anderson was Senior Vice President, R&D and Operations and General Manager for Somanetics from 2007 until the completion of the integration with Covidien in 2011. Mr Anderson has also served as Director of Product Development at Delphi Medical Systems, a provider of technology and products to the infusion, respiratory care, vital signs monitoring and power mobility medical device markets. In addition, he was President and Chief Executive Officer of Tasso Solutions, a product development and manufacturing consulting firm. Mr Anderson retains Board positions on the University of Michigan Medical School MTRAC Board, which oversees investment in medical technology, and the University of Michigan Ross School of Business Zell Lurie Healthcare Board which oversees student investment in emerging technology via the Zell Lurie Commercialization Fund.

Timothy A. Marcotte
Timothy A. Marcotte

Chief Financial Officer

Tim has more than 25 years of experience as a senior executive focused on strategic planning, equity and debt financing and investor relations. He has led multiple initial public offerings and merger and acquisition transactions. Tim has been a public company Chief Financial Officer for many years, as well as serving as a Chief Operating Officer and Chief Executive Officer. He has built strong teams and is a proven leader. Tim served most recently as the CEO and CFO of ZONARE Medical Systems, a diagnostic ultrasound company and as CFO at VNUS Medical Technologies, a company focused on treating vascular disease. In addition, he has held several interim senior executive assignments at early stage technology companies. Tim graduated with a Bachelor of Science and Master of Business Administration from the University of Michigan.

Rob Turnbull
Rob Turnbull

Vice President of Finance & Business Services

Rob has over 25 years’ corporate experience, starting his career with PricewaterhouseCoopers where he worked in Auckland, Toronto, and London; and has over 15 years’ experience with technology and life‑sciences companies. Rob has also been Chief Financial Officer for an ASX-listed biotech company undertaking multiple international studies ranging from preclinical to clinical Phase 3, and with operations in the United States, Australia and New Zealand. In addition to capital markets financing and compliance, treasury, tax, financial reporting, commercial contract negotiations and general management, he has been involved in M&A activity to acquire and develop specific technologies. Rob graduated from Auckland University with a Bachelor of Commerce, and is a Chartered Accountant and member of Chartered Accountants Australia and New Zealand.

Nigel Devine
Nigel Devine

Vice President Production & Development

Nigel has over 38 years’ experience in manufacturing, engineering and operations, starting his career with British Aerospace where he worked in the UK before emigrating to New Zealand in 1995, and has held a number of senior and executive positions with a number of technology companies including OSCMAR International Ltd, Cubic Defense (NZ) Ltd, Boeing (USA) and Dyson Ltd (Malaysia). 

Most recently Nigel was Vice President of Global Operations for NextWindow Ltd a New Zealand Technology company. For the last five years of the role Nigel was based in Singapore, setting up and developing an office to support operations across Asia. Nigel was responsible for the entire supply chain, procurement, manufacturing and New Product Introduction (NPI) and had a team spread across Asia and New Zealand. 

Nigel graduated from the University of Huddersfield (UK) with a 1st Class Bachelor of Engineering in Computer Aided Engineering and is a Chartered Engineer and a member of the IET.

Vik Panda
Vik Panda

Vice President of Marketing

Vik has senior experience with direct-to-consumer marketing where he has built communities of millions of users. Prior to joining Adherium, Vik gained extensive experience in both the data and wellness sectors. Most recently, he was CEO at Findyr, a crowdsourcing data collection platform, and before that, he was Chief Marketing Officer at Fitocracy; he has also worked at Citigroup, Nokia and others. Vik has a Master of Business Administration from INSEAD, a Bachelor of Arts and Master of Arts from New York University, and has completed the Chartered Financial Analyst program.

Chris Mander
Chris Mander

Head of Regulatory & Quality

Based in New Zealand, Chris has over 25 years’ experience of the medical device manufacturing sector. He has worked for companies with a strong focus on international export, including Fisher & Paykel Healthcare. 

Chris has focused on regulatory affairs and quality management for over 20 years, with extensive experience in obtaining United States and European market entry clearance and implementing quality management systems. Chris has also held positions with responsibilities including procurement, manufacturing, product management, and intellectual property. 

Chris graduated from Auckland University with a Bachelor of Science in Physics, Chemistry, Mathematics and Bachelor of Engineering in Electrical and Electronics.

Maggie Scott
Maggie Scott

Head of Clinical Operations

Maggie has over 25 years’ experience in the healthcare and biotech industry at a senior management level. This includes 14 years managing a full service, New Zealand based CRO. Maggie has overseen the conduct of multiple clinical trials covering all phases of study and including the successful registration of two products under the US FDA’s NDA process. She has worked with a variety of international pharmaceutical and biotech companies and has a strong background in clinical operations and quality management. 

Maggie qualified as a registered nurse from St Bartholomew’s Hospital, London and as a health care auditor in New Zealand.

Scott Fleming
Scott Fleming

Senior Vice President Business Development Europe

Scott is a founding member of the digital drug delivery movement. With 25 years’ sector experience covering strategy, drug device development, and sales & marketing.

After gaining an interest in drug delivery performing Business Development at the PA Consulting Group, Scott co-founded MicroDose Therapeutx in 1997, developing the first totally digital dry powder inhaler. During his tenure as Sr. Vice President and Board Member, he led MicroDose’s strategy and executed numerous licensing and development collaborations with Bristol-Myers Squibb, Novartis AG, Merck & Co. and Gilead Sciences Inc., among others, for respiratory programs using the digital inhaler and associated in-house molecules.

Scott engineered the sale of MicroDose to Teva Pharmaceuticals in 2013, and took on a key role as the Global Brand Lead for eConnectivity of Teva’s respiratory franchise based in Amsterdam, NL responsible for the commercial and branding strategy for eConnectivity of Teva’s inhaler products.

Scott is based in Amsterdam, the Netherlands, where Adherium’s European operations is located and will continue to develop Adherium’s partnerships within the key European market and beyond.

Scott graduated cum laude from Middlebury College with Bachelor of Science and Bachelor of Arts degrees in Geology and Music respectively and spent 11 years in the petroleum industry with Schlumberger Ltd before moving to the healthcare industry.

Meet the board

The Adherium board of directors bring together individuals with multidisciplinary and complementary skill sets which support Adherium’s current and future objectives.

Mr Thomas Lynch
Mr Thomas Lynch

Independent Non-Executive Chair

Appointed 1 September 2016

Mr Lynch has extensive capital markets experience in the internationalisation of the healthcare sector. He has recently stepped down as chair of Icon plc, one of the world’s largest clinical research organisations having served on its board for 22 years. Mr Lynch is currently a Chairperson at several notable organisations, including Evofem Holdings, Evofem, Dublin Academic Medical Centre, Sigmoid Pharma, Molecular Medicine Ireland and the Queen’s University of Belfast Foundation. Mr Lynch also serves as a non-executive director of GW Pharma plc, a biotechnology company listed on NASDAQ and AIM. In a pro-bono capacity, Mr Lynch serves as chair of the Ireland East Hospital Group, the largest hospital group in Ireland. Mr Lynch has also served in a range of roles at Elan Corporation plc and Amarin Corporation plc. Throughout his career, Mr Lynch has been involved in the listing of a number of companies on the NASDAQ market and brings significant international capital markets experience to Adherium. Mr Lynch has held no other Australian public company directorships in the last three years.

Mr Jeremy Curnock Cook, MA.
Mr Jeremy Curnock Cook, MA.

Non-Executive Director

Appointed 17 April 2015

Mr Curnock Cook was formerly head of the life science private equity team at Rothschild Asset Management in the UK and an active investor in the Australian life science sector. At Rothschild, Mr Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock Cook has specialised in creating value in emerging biotech enterprises, through active participation with management. He has served on over 40 boards in various roles, including chair of private and public biotechnology companies listed on NASDAQ, LSE, TSX and ASX. Mr Curnock Cook received his MA in Natural Sciences from Trinity College in Dublin, Ireland. He is currently Managing Director of BioScience Managers (manager of a major shareholder in Adherium), Chairperson of Avena Therapeutics and AmpliPhi Biosciences and sits on the board of Avita Medical, Rex Bionics Pty and acts as an alternative director for Sea Dragon Ltd. Mr Curnock Cook was previously a director of Bioxyne Limited and Phylogica Limited. He has held no other Australian public company directorships in the last three years.

Dr William (Bill) Hunter MD MSC
Dr William (Bill) Hunter MD MSC

Independent Non-Executive Director

Appointed 17 December 2015

Dr Hunter has extensive experience in commercialising medical device technologies. He co-founded Angiotech Pharmaceuticals in 1992 and assumed the position of CEO in 1997 when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through its IPO and listing on the Toronto Stock Exchange and NASDAQ. Dr Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-investor, including the TAXUS® Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, the Quill barbed wound closure device and the 5-FU Anti-Infective Catheter. Combined, these products have generated revenues of over $12 billion and have helped the lives of over 6 million patients globally. He is currently President and CEO of Cardiome Pharma Corp (NASDAQ: CRME), a Director of Rex Bionics, Co-Founder of Canary Medical and is an Industry Expert Advisor for BioScience Managers (manager of a major shareholder in Adherium). He has previously served as a director of Epirus Biopharmaceuticals (NASDAQ: EPRS) and Union Medtech. Dr Hunter completed his BSc from McGill University and a MSC and MD from the University of British Columbia. Dr Hunter served as a practising physician in British Columbia for five years. Dr Hunter held no other Australian public company directorships in the last three years.

As noted, as an Industry Expert Advisor for BioScience Managers, Dr Hunter has an association with a significant shareholder of the Company. The board of directors is of the opinion that this does not compromise Dr Hunter’s independence as to the best of the board’s knowledge he is not involved in decision making by BioScience Managers and the value of the advisory services provided is not material.

Mr Bruce McHarrie BCom, FCA, GAICD
Mr Bruce McHarrie BCom, FCA, GAICD

Independent Non-Executive Director

Mr McHarrie is currently an independent director and consultant with over 20 years’ experience in the health and life sciences sectors. He was formerly with Telethon Kids Institute in Perth, Western Australia, for 15 years, where his roles included Chief Financial Officer, Director of Operations and Director of Strategic Projects. Prior to joining Telethon Kids, Mr McHarrie was a Senior Manager at Deloitte in London before moving to Rothschild Asset Management as Assistant Director of the Bioscience Unit, a life sciences private equity group investing in early stage biotechnology and healthcare companies. Outside his role at Adherium, he is currently an advisor to BioScience Managers (manager of a major shareholder in Adherium), a director at AusCann (Australasian Medical Cannabis) and an independent consultant. Bruce is a Fellow of the Institute of Chartered Accountants Australia and New Zealand. He holds a Bachelor of Commerce from the University of Western Australia and is a graduate member of the Australian Institute of Company Directors. Until recently, Mr McHarrie served as a non-executive director and chairman on the board of ASX listed company, Phylogica Limited. Mr McHarrie has held no other Australian public company directorships in the last three years.

As noted, as an advisor to BioScience Managers, Mr McHarrie has an association with a significant shareholder of the Company. The board of directors is of the opinion that this does not compromise Mr McHarrie’s independence as to the best of the board’s knowledge he is not involved in decision making by BioScience Managers and the value of the advisory services provided is not material.

Professor John Mills, AO, SB, MD, FACP, FIDSA, FRACP.
Professor John Mills, AO, SB, MD, FACP, FIDSA, FRACP.

Independent Non-Executive Director

Appointed 20 July 2015

Professor Mills is an internationally-regarded physician, scientist and biotechnology businessman. He was recruited from the US to Melbourne 25 years ago as the managing director of the Burnet Institute of Medical Research and Public Health. Since then Professor Mills has been managing director of an ASX-listed company, Narhex Life Sciences, chairman of another ASX-listed company, AMRAD Corp., executive chairman of a Swedish biotechnology company, Cavidi AB and non-executive director of a further ASX listed company, Phosphagenics Corp. Ltd. Thirteen years ago he co-founded a boutique anatomic pathology practice, TissuPath Specialist Pathology. Before taking his current position as Director of R&D at TissuPath, he served as Managing Director for three years. He is currently an investment committee member at an Australian venture capital firm, GBS Venture Partners. Professor Mills is an honours graduate of the University of Chicago and Harvard Medical School, and is a Fellow of both the US and Australian Colleges of Physicians. His expertise is in infectious diseases and pulmonary diseases. He maintains a clinical practice at The Alfred Hospital in Melbourne. Professor Mills has held no other Australian public company directorships in the last three years.

Mr Bryan Mogridge BSc, ONZM, FNZIOD
Mr Bryan Mogridge BSc, ONZM, FNZIOD

Independent Non-Executive Director

Appointed 20 July 2015

Mr Mogridge has been a successful public company director for over 30 years. He has been CEO of two listed companies and has a background in science, manufacturing, investment and technology. His business philosophy is to be invested where he is involved and grow value for all shareholders. Mr Mogridge is currently Chairperson of Rakon Ltd and sits on the Board as a Director of Mainfreight, Clearspan, BUPA ANZ and Thinxtra. He also recently joined as a director of Auckland Regional Amenities Funding Board. Mr Mogridge also has significant involvement in philanthropy, chairing one of New Zealand’s most successful charities (The Starship Foundation) for 20 years, helping to transform sick children’s lives through New Zealand’s national children’s hospital “The Starship”. Mr Mogridge is currently a Trustee for The Starship Foundation. He has previously held directorships at Yealands Wine Group, Momentum Energy, Waitakere City Holdings, Enterprise Waitakere, Pyne Gould Corporation. Mr Mogridge has also previously chaired national organisations such as the NZ Wine Institute, the NZ Food and Beverage Exporters Council and the NZ Tourism Board. He was previously deputy chair of UBS NZ and chair of ASX-listed Lantern Hotel Group having resigned in June 2015 and held no other Australian public company directorships in the last three years.

Mr Garth Sutherland, MSc, MAICD.
Mr Garth Sutherland, MSc, MAICD.

Founder & Executive Director

Appointed 20 July 2015

Mr Sutherland founded Adherium in 2001 (formerly known as Nexus6). Having had asthma all his life he wanted a solution for automatically tracking his asthma medication use to improve his asthma management. He is an inventor of 13 patent families related to the Smartinhaler™ platform and a contributor to over 70 registered designs and several trademarks registered or used by Adherium. Prior to Adherium, Mr Sutherland worked in a variety of commercial, marketing and engineering roles. He has spent over 20 years working for some of the world’s top technology companies in Europe, North America and Australasia including Microsoft and Gallagher Group. Mr Sutherland graduated with a Masters of Science in Physics from the University of Waikato, New Zealand, with First-Class Honours. Mr Sutherland has held no other Australian public company directorships in the last three years.

Working at Adherium

We don’t currently have any open roles, but we are always on the lookout for amazing and highly skilled people – if this is you then please get in touch.

Get in touch